Needleless Advantage Altea's PassPort patch enables needle-free, self-administered delivery through microchannels created by focused thermal energy, supporting rapid and sustained uptake of proteins, peptides, carbohydrates and small molecules, reducing clinician time and improving patient convenience—a strong hook for vaccine developers, biologics teams and outsourcing partners seeking dermal delivery options.

Biologics Fit The platform is well-suited for biologics and vaccines that benefit from non-invasive administration, presenting sales opportunities with biotech and pharmaceutical companies pursuing scalable, patient-friendly delivery modalities and potential collaborations with contract manufacturing organizations.

IP and Partnerships A robust patent portfolio enables licensing or co-development deals with large pharma or CDMOs seeking to augment their portfolio with a dermal delivery platform, reducing R&D risk through established protection.

Growth Capital Private equity-backed growth signals from multiple investors indicate appetite for strategic collaborations, equity partnerships, or milestone-driven deals to accelerate product pipeline commercialization.

Market Positioning Position as a specialized dermal delivery partner to supplement or augment existing drug manufacturing lines, creating opportunities to collaborate with major contract manufacturers and pharma service providers.